# Psilocybin

Type: Technology

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/psilocybin-technology
Canonical HTML page: https://gethealthbrief.com/entity/psilocybin-technology

## Timeline

- **2026-03-15**: Valuation Period — Expected timeframe for determining the fair market value of the equity investment.
- **2026-03**: Palliative Care Findings — New research confirms high efficacy rates for mitigating end-of-life distress in oncology settings.
- **2026-02-20**: Option Exercised — PsyLabs officially triggers the put option, requiring an equity investment from PBM.
- **2025-01-01**: Put Option Established — Psyence BioMed and PsyLabs enter into a strategic put option agreement.
- **2022-01**: SAP Expansion — Canada formally expands the Special Access Program to include restricted psychedelic substances.
- **2020-08**: Canadian Exemptions — Health Canada grants the first legal exemptions for psilocybin use to four terminally ill patients.
- **2018-10**: FDA Breakthrough Status — FDA grants Breakthrough Therapy designation to psilocybin for treatment-resistant depression.

## Recent coverage (2 stories)

### Psilocybin Research Signals Paradigm Shift in End-of-Life Palliative Care
2026-03-06 15:49:55 · Sentiment: Positive · Impact: 7/10 · Sources: 2

Clinical research into psilocybin-assisted therapy is demonstrating significant potential in mitigating existential distress and depression among terminally ill patients. These findings are driving a re-evaluation of palliative care protocols and accelerating the push for expanded regulatory access to psychedelic-based treatments.
Full story: https://gethealthbrief.com/story/psilocybin-palliative-care-research-trends

### Psyence BioMed Strengthens Supply Chain with Strategic PsyLabs Investment
2026-02-21 00:39:13 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Psyence Biomedical Ltd. (Nasdaq: PBM) has confirmed a strategic equity investment in PsyLabs following the exercise of a previously established put option. This move deepens the integration between the biopharmaceutical developer and its primary manufacturer of pharmaceutical-grade psychedelic compounds.
Full story: https://gethealthbrief.com/story/psyence-biomed-psylabs-equity-investment-put-option

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.